WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced that it will be participating in two investor conferences in September.
AtriCure management is scheduled to present at the Stifel 2013 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 12, 2013 at 9:45 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com.
AtriCure management is also scheduled to participate in the 6th Annual Barrington Research Growth Conference in Chicago on September 4, 2013.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.